异质性万古霉素中介金黄色葡萄球菌对临床细菌感染治疗的影响

Impact of heteroresistant vancomycin intermediate Staphylococcus aureus on antimicrobial therapy of bacterial infections

以往认为细菌不易对万古霉素产生耐药，但近年来国际上许多国家和地区报道了万古霉素的耐药性现象，其中异质性万古霉素中介金黄色葡萄球菌（hVISA）受到了关注，因其发生率上升而又不易被检测，影响了细菌感染的治疗。本期刊登了王辉教授课题组以可靠的检测方法对分离自我国14个城市的甲氧西林耐药金黄色葡萄球菌进行了hVISA检测，首次发现hVISA在我国的发生率高，应引起临床医师的重视。

Vancomycin resistance in Staphylococcus aureus （hVISA） has been reported worldwide in recent years, although it was previously thought that vancomycin resistance was seldom. Heteroresistant vancomycin intermediate hVISA has strong impact on the efficacy of vancomycin treatment and it＇s prevalence has been increasing. However, hVISA is uneasy to be detected. In this issue, Wang Hui research group reports the high prevalence of hVISA, which was detected with reliable method, in MRSA strains collected from 14 cities in China. This finding should attract clinician＇s attention.